A nonsense mutation is a substitutive mutation in a DNA sequence that causes a premature termination during translation and produces stalled proteins resulting in dysfunction of a gene.
Introduction
Nonsense mutations, in which premature termination codons (PTCs) are formed by base pair substitution, truncate protein synthesis during translation. Such gene dysfunction is a source of severe pathological phenotypes in genetic diseases. Hence, compelling ribosomal read-through of the full coding sequence is a reasonable strategy for treating such genetic disorders. To address this issue, previous studies showed to induce the skipping of exons containing PTCs by using antisense oligonucleotides (AONs) 1, 2 . In other way, a few small-molecule drugs such as ataluren 3, 4 and aminoglycosides 5 (e.g., gentamicin) have been utilized to bypass nonsense mutations by introducing near-cognate tRNAs at the site of the PTC 6, 7 . However, those approaches act transiently and have nonspecific effects for the drugs. Alternatively, CRISPRmediated homology-directed repair (HDR) can be used for gene correction, but is limited by low correction efficiency, especially in differentiated non-replicating cells from higher eukaryotes including humans 8, 9, 10 .
It was reported that CRISPR-mediated base editing technologies enable highly efficient direct conversion of DNA bases without producing double-strand breaks (DSBs). Cytidine deaminase-based base editors (BEs) produce C-to-T or G-to-A substitutions between the fourth and eighth bases in the non-binding strand of single-guide RNA (sgRNA) at protospacer DNA 11, 12 . On the other hand, A-to-G or T-to-C transitions in the same DNA positions can be achieved by adenine base editors (ABEs) 13 . In addition to the initial versions of BEs and ABEs, Koblan et al 14 improved the base editing activities by expression optimization and ancestral reconstruction, which were named BEmax and ABEmax, respectively. Moreover, Hu et al 15 and Nishimasu et al 16 independently developed new Cas9 variants, named xCas9 and SpCas9-NG, that recognize 5'-NG-3' with 5'-NAR-3' sequences, expanding the targetable sites.
To date, a few groups reported to successfully correct target gene by restoring open reading frame in PTCs by using the ABEs such as a TAG-PTC of EGFP gene in rice 17 , both TAA-PTC of Tyr gene and TAG-PTC of DMD gene in mice 18 . However, although a few meaningful examples were shown, the systematic gene rescue for all possible cases are not demonstrated yet. It is expected that by targeting the coding strand with ABEs, the three possible PTCs, 5'-TAA-3', 5'-TAG-3', and 5'-TGA-3', can be converted to 5'-TGG-3', which will be translated to tryptophan (Trp). Alternatively, by targeting the noncoding strand, the three PTCs can be converted to 5'-CAA-3' (translated to glutamine; Gln), 5'-CAG-3' (Gln), or 5'-CGA-3' (arginine; Arg), respectively (Fig. 1a) . In this study, we established an ABE-mediated read-through method, named CRISPRpass, to bypass PTCs by converting adenine to guanine or thymine to cytosine. We constructed all type of PTCs knock-in (KI) cell lines and then showed the read-through for all cases.
Ultimately, we showed gene rescue at a patient-derived fibroblast containing PTC.
Results
In silico investigation of applicable targets for CRISPR-pass in the ClinVar database.
We first inspected all targetable variations registered in the ClinVar database in silico to investigate how many genetic diseases with nonsense mutations could potentially be treated with CRISPR-pass. Of the 50,376 mutations causing pathological phenotypes in the database, nonsense mutations account for 16.2% (Fig. 1b) ; among these, 41.1 % are targetable by conventional ABEs that recognize a canonical protospacer adjacent motif (PAM), 5'-NGG-3', and 95.5% are covered by a recently engineered ABE, xCas9 3.7-ABE 7.10 (called xABE here), which recognizes a non-canonical set of PAMs, 5'-NG-3', and 5'-NAR-3' (Fig. 1c) . Only 31.5%
of the nonsense mutations in the database can be exactly corrected to amino acids found in the non-mutant protein by xABEs, implying that the set of mutations that can be modified for readthrough by CRISPR-pass is much larger than the set for which exact gene correction in DNA is possible ( Fig. 1c and Supplementary Data 1).
Construction of six knock-in HeLa cell lines carrying various types of PTCs in EGFP gene.
To demonstrate the efficiency of CRISPR-pass in human cells, as a proof of concept, we tried to construct six knock-in HeLa cell lines, each carrying a different mutated version of the enhanced green fluorescent protein (EGFP) gene. We first prepared six DNA plasmids having different types of PTCs in the EGFP gene. The mutant EGFP genes as a set contain each type of PTC at two locations: the three PTCs in a position that can be converted by targeting the coding strand and the three PTCs in a position that can be converted by targeting the non-coding strand. The first position corresponds to a codon for lysine (Lys53) and the second to a codon for aspartate (Asp217); the encoded residues are located in connecting loop domains of EGFP ( Fig. 2a and Supplementary Fig. 1 ). After preparing plasmids containing the six mutated EGFP genes, each plasmid was inserted into the genome in an endogenous safe-harbor region, the AAVS1 site 19 , using CRISPR-Cas9 via a non-homologous end-joining (NHEJ) pathway 20 ( Fig. 2b) . The cell lines were named c-TAA, c-TAG, c-TGA, nc-TAA, nc-TAG, and nc-TGA, respectively.
CRISPR-pass rescues the function of EGFP gene in six knock-in HeLa cell lines.
To test whether ABE treatment would allow bypass of these nonsense mutations, we transfected plasmids expressing sgRNAs designed to target both locations harboring PTCs, together with ABE-encoding plasmids, into the prepared HeLa cell lines. After ABE treatment by lipofection, we found that functional EGFP was expressed, as seen by green fluorescence, in all cell lines. For example, in the case of c-TAA cells, the function of EGFP would be rescued when two adenines are changed to guanines simultaneously for bypassing the PTC. As shown in Figure 2c , the functional EGFPs were observed after various ABEs (ABE 7.10, xABE, and ABEmax) were treated. We quantified the ratios of rescued to mutated EGFPs by fluorescenceactivated cell sorting (FACS) analysis (Fig. 2d) . We also confirmed the A to G conversion at target DNA region by targeted deep sequencing in bulk cell populations; the conversion rate of two adenines (A 7 A 8 ) to two guanines (G 7 G 8 ) was 11.2% here ( Table 2 ). It is noteworthy to mention that ABEmax was the most effective one in all cases, resulting in up to 59.6% rescue of the mutant EGFP gene, compared to the ABE7.10 and xABE.
CRISPR-pass rescues the function of XPC gene in patient-derived fibroblasts.
We next applied CRISPR-pass to the rescue of a nonsense mutation in fibroblasts (GM14867)
derived from a patient with xeroderma pigmentosum, complementation group C (XPC). XPC, which affects the skin, is a genetic disorder caused by nonsense mutations in the XPC gene.
The XPC protein is an initiator of global nucleotide excision repair 21 . Thus, XPC-deficient cells accumulate DNA damage when they are exposed to chemical or physical stimuli including ultraviolet irradiation 22 . GM14867 cells have a homozygous C>T nonsense mutation at nucleotide 1840 in the XPC gene, which creates a 5'-TGA-3' stop codon that replaces a codon for arginine (Arg579) (1840C>T, Arg-579-UGA stop codon) (Fig. 3a) . After treating GM14867 cells with ABE7.10-encoding plasmid and sgRNA-encoding plasmid by electroporation, the adenine base in the 5'-TGA-3' stop codon was converted to guanine to create 5'-TGG-3' at a rate of 3.4%, as measured by targeted deep sequencing ( Supplementary Fig. 4 ), indicating partial rescue of the XPC gene. Similar to the previous experiments, xABE and ABEmax resulted in higher base editing rates more than 10% ( Supplementary Fig. 4 and Fig. 3b ),
respectively. Western blot analyses demonstrated that both xABE and ABEmax treatment led to recovery of expression of the full-length XPC protein, with a molecular weight similar to that in wild-type (WT) cells (ARPE-19), at considerably higher levels than induced by ataluren or gentamicin (Fig. 3c) .
Next, to determine the functional activity of the recovered XPC protein, we evaluated the viability of GM14867 cells at 72 hours after exposure to 254 nm ultraviolet light. To our surprise, both xABE-and ABEmax-treated GM14867 cells had significantly regained resistance to ultraviolet irradiation-induced DNA damage, causing an increase in cellular viability (Student's ttest, P<0.001, Fig. 3d ). More importantly, ABEmax-treated GM14867 cells sustained such XPC protein expression for at least 4 weeks, whereas the cells treated with ataluren or gentamicin gradually lost XPC protein expression ( Fig. 3e and Supplementary Fig. 5 ), implying that CRISPR-pass inducing persistent expression for the nonsense mediated disease therapies.
Finally, to examine the off-target effects of CRISPR-pass in GM14867 fibroblasts, we searched for potential off-target sites using Cas-OFFinder 23 and carried out targeted deep sequencing for 12 candidate target sites (Supplementary Fig. 6 and Supplementary showed that the A-to-G conversions at a rate of about 10% can rescue the expression of functional XPC protein (Fig. 3b-3d ) without detectable off-target effects, strongly indicating that the CRISPR-pass is a relevant approach for rescuing the nonsense associated diseases with higher editing efficiencies than using HDR 32 and without the loss of large portion of protein via the exon removal 33 or skipping strategies 34 . More importantly, CRISPR-pass induced prolonged XPC protein expression unlike ataluren and gentamycin that are known as current nonsense mutation disease therapy 3, 5 .
Recently, it is reported that DNA cleavages at on-target site frequently cause undesired large deletions or complex genomic rearrangements 35 . In this aspect, CRISPR-pass has important safety advantages relative to approaches that do rely on DNA cleavage. Furthermore, recent off-target profiling experiments on ABEs supported the high specificity of ABEs 24, 25, 26 , increasing the potential clinical utility of it. These characteristics suggest that CRISPR-pass might be useful for gene rescue in a clinical setting, as an alternative to existing drugs.
Methods
General methods and cloning. All kinds of ABEs were purchased from addgene (pCMV-ABE Primer sequences for cloning are in Supplementary Table 4 and Supplementary Table 5 .
ClinVar database analysis. Bioinformatic analysis of the ClinVar database of human diseaseassociated mutations was conducted using Python. The ClinVar database (Common_and_clinical_20170905) was used for this analysis.
The Python script used to analyze mutation patterns in human diseases and to identify mutations that could be CRISPRpass targets can be accessed at website (https://github.com/Gue-ho/CRISPR-pass). Briefly, the steps of the analysis were as follows:
1-1) Among entries in the ClinVar database, we identified mutation patterns in the following categories: indels (insertions or deletions), silent mutations, nonsense mutations, and missense mutations. 1-2) For precise analysis, entries in each mutation pattern category were subdivided depending on their nucleotide sequence using information about the surrounding genomic sequence and coding sequence (CDS). CDSs were extracted from the SNP database at NCBI.
If no CDS was found in NCBI than data were taken from GRCh38 and hg19.
2-1) Among the sorted entries from the ClinVar database, the number of nonsense mutations that were potential CRISPR-pass targets were counted. The targetable Cas9 sites were grouped by their associated PAM sequences, such as GG, AG, GA, GC, GT, GAN, and AA. 2-2) Each Cas9-targetable site was filtered depending on the ABE target range (position 4 to 8 in the protospacer from the end distal to the PAM) it contained. 2-3) To prevent counting sequences more than once, in the case of SpCas9, a sequence was counted when at least either GG or AG was possible; the number was counted as a targetable PAM for xABE when at least one of the PAM was possible.
Cell culture and transfection. HeLa (ATCC, CCL-2) cells were grown in Dulbecco's Modified
Eagle Medium (DMEM) with 10% fetal bovine serum (FBS) and a penicillin/streptomycin mix (100 units/mL and 100 mg/mL, respectively). Targeted deep sequencing. Genomic DNA segments that encompass the nuclease target sites were amplified using Phusion polymerase (New England Biolabs). Equal amounts of the PCR amplicons were subjected to paired-end read sequencing using Illumina MiSeq at BioMedical Science Co. (South Korea). Rare sequence reads that constituted less than 0.005% of the total reads were excluded. Off-targets were selected by Cas-OFFinder (http://www.rgenome.net/cas-offinder/) 23 and base substitutions were analyzed by BE-Analyzer (http://www.rgenome.net/be-analyzer/) 39 . Primer sequences and List of off-targets are in Supplementary table 5 and Supplementary table 6 .
Treatment with ataluren and gentamicin. GM-14867 cells and the cells treated with xABE and
ABEmax were maintained in EMEM with 15% FBS. When the confluency was 60-70%, the cells were treated with ataluren (10 µM; cat. no. S6003, Selleck) or gentamicin (1 mg/mL; cat. no.
G1397, Sigma) for 48 h.
Western blotting. Cell lysates were homogenized in 1X cell lysis buffer (cat. no. #9803, Cell
Signaling Technology) and the supernatants were collected after centrifugation for 10 minutes at 14,000 g. An equal amount (35 µg) of the protein was separated by SDS-PAGE in 4-15% Mini-PROTEAN ® TGX ™ Precast Protein Gels (cat. no. 4561084, Bio-Rad) and transferred to nitrocellulose membranes. The membranes were incubated with primary antibodies overnight at 4°C. The primary antibodies utilized in this study were as follows: anti-XPC antibody (cat. no.
MA1-23328, Thermo), and anti-β-actin antibody (catalog no. A2668, Sigma). Then, the membranes were treated with the appropriate species-specific secondary antibodies (cat. no.
sc-2357 and sc-516102, Santa Cruz) for 1 h at room temperature. After treatment of the membranes with reagents from the EZ-Western Lumi Pico Kit (cat. no. DG-WP100, DoGEN), the protein bands were visualized using the ImageQuant LAS4000 system with the accompanying software program (GE). 
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